Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis

Journal:

Nature Communications

Published:

2026-01-12

DOI:

10.1038/s41467-025-67824-z

Affiliations:

25

Authors:

23

Go to article

Institutions	Authors	Share
Pfizer, United States of America (USA)	3.000000	0.13
Mayo Clinic Hospital - Phoenix, United States of America (USA)	2.000000	0.09
Duke University Health System, United States of America (USA)	1.000000	0.04
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.04
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.000000	0.04
University Hospitals Leuven (UZ Leuven), Belgium	1.000000	0.04
Texas Oncology, United States of America (USA)	1.000000	0.04
Mayo Clinic, United States of America (USA)	1.000000	0.04
Roswell Park Cancer Institute (RPCI), United States of America (USA)	1.000000	0.04
Oregon Health and Science University (OHSU), United States of America (USA)	1.000000	0.04
USC Norris Comprehensive Cancer Center, United States of America (USA)	1.000000	0.04
Vanderbilt University Medical Center (VUMC), United States of America (USA)	1.000000	0.04
Vall d'Hebron University Hospital (HUVH), ICS, Spain	1.000000	0.04
University Hospitals Cleveland Medical Center, CWRU, United States of America (USA)	1.000000	0.04
University Hospital of Pisa, UNIPI, Italy	1.000000	0.04
Aurora Health Care System, United States of America (USA)	1.000000	0.04
University of Milan (UNIMI), Italy	0.500000	0.02
Niguarda Hospital, Italy	0.500000	0.02
Sorbonne University, France	0.500000	0.02
Saint Antoine Hospital, France	0.500000	0.02
Fred Hutchinson Cancer Center, United States of America (USA)	0.500000	0.02
University of Washington (UW), United States of America (USA)	0.500000	0.02
Weill Cornell Medicine, United States of America (USA)	0.500000	0.02
City of Hope, United States of America (USA)	0.500000	0.02

Interested in Oncology and Carcinogenesis?